Skip to content

Alumis Inc. ALMS Debt-to-equity

Debt-to-equity at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
2.2×-0.6×
Amgen logo
AmgenAMGN
6.2×-3.0×
Oruka Therapeutics, Inc. logo
Oruka Therapeutics, Inc.ORKA
0.0×
Celldex Therapeutics logo
Celldex TherapeuticsCLDX
0.0×
Immunome logo
ImmunomeIMNM
0.0×
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
0.1×-7.2×

Other financials

Income statement

See full
Revenue$1.7M-90.0%
Operating income-$98.4M+3.1%
Net income-$93.1M+6.0%
EPS (diluted)-$0.74+59.3%

Balance sheet

See full
Cash & equivalents$63.9M-50.3%
Total debt$35.7M+1,881%
Total equity$567.0M+237%
Total assets$671.6M+157%

Cash flow

See full
Operating cash flow-$87.1M-8.4%
CapEx$164.0K+343%
Free cash flow-$87.2M-8.5%

Valuation

See full
Market cap$3.12B+739%
Enterprise value$3.1B+1,238%
P/S371.9×

Profitability

See full
Operating margin-5,364%
Net margin-2,825.7%
FCF margin-4,487.4%

Returns & leverage

See full
Return on equity-64.6%
Current ratio7.5×+3.8×

Where this comes from

Calculated from Alumis Inc.’s reported figures.

Based on the most recent quarter.

The official record: Alumis Inc.’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about Alumis Inc.'s debt-to-equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Alumis Inc.'s debt-to-equity?
Alumis Inc. (ALMS) reported debt-to-equity of 0.1× in Q1 2026.
How has Alumis Inc.'s debt-to-equity changed year-over-year?
Alumis Inc.'s debt-to-equity increased by 487.9% year-over-year, from 0× to 0.1×.
What does debt-to-equity mean?
Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.